Search
Close this search box.

Is breastfeeding in MS harmful or not? An answer from real-world Czech data

Original paper from Pavel Hradílek, MD, Ph.D. from the University Hospital Ostrava based on data from the ReMuS registry was published in the professional journal Multiple Sclerosis and Related Disorders.

Hradilek, P., Zapletalova, O., Hanulikova, P., Havrdova, E. K., Woznicova, I., Mazouchova, A., Drahota, J., Lauer, M., Stetkarova, I., Valis, M., Libertinova, J., Stourac, P., Adamkova, J., Ampapa, R., Vachova, M., Dufek, M., Martinkova, A., Peterka, M., Recmanova, E., Mares, J. Horakova, D. (2023). Is breastfeeding in MS harmful or not? An answer from real-world Czech data. And Multiple Sclerosis and Related Disorders (Vol. 76, p. 104790). Elsevier BV. https://doi.org/10.1016/j.msard.2023.104790 PMID: 37348317

Abstract

Background: The influence of breastfeeding and it´s duration on the course of multiple sclerosis (MS) is unclear. Here we analyzed a real-world data for breastfeeding women with MS and their disease course collected from a Czech national registry ReMuS.

Aims: To identify risk factors associated with not initiating breastfeeding after delivery, to analyze the impact of breastfeeding on the MS disease course, evaluate the assumption, that breastfeeding is not harmful in MS patients, and compare the disease course by breastfeeding status.

Procedure and methods: Using propensity score matching we compared Expanded Disability Status Scale (EDSS), confirmed disease worsening (CDW) and annual relapse rate (ARR) in breastfeeding and non-breastfeeding MS patients according to disease duration, disease modifying treatment (DMT) before pregnancy, last EDSS score before conception, age, and ARR during pregnancy. We also compared these parameters between breastfeeding patients not using a DMT and non-breastfeeding patients who resumed DMT within 3 months after delivery. EDSS, ARR, and CDW were collected at 12, 24, and 36 months after delivery.

Results: A total of 1681 pregnancies that ended in delivery were analyzed from 2013 through 2020. Change in ARR and EDSS values and 6-months CDW did not significantly differ between the analyzed groups. Compared with non-breastfeeding women who resumed DMT early after delivery, breastfeeding women with MS did not experience worse clinical outcomes even without initiating a DMT.

Discussion: Breastfeeding in Czech women with MS did not negatively affect the disease course and can be supported. Patients with MS can be treated with certain DMTs alongside breastfeeding and there is no need to stop breastfeeding, if the patient is clinically stable.

Entire paper is available after login to the website of the Multiple Sclerosis and Related Disorders.

Archive

Page intended exclusively for healthcare professionals

Dear Visitors,

Please be informed that the following webpage is intended exclusively for healthcare professionals as defined by the advertising regulation law, specifically for individuals authorized to prescribe or dispense medicinal products.

The content of this page is therefore not intended for the general public, particularly not for everyday consumers. There is a risk that the information could be misunderstood or misinterpreted by those without the appropriate expertise, potentially leading to incorrect diagnoses or treatment decisions, and thus posing a health risk.

I declare that I am a healthcare professional and acknowledge that the information displayed here is not intended for the general public.

Newsletter of the ReMuS registry

Occasionally, we will send you news from the field of multiple sclerosis research and the ReMuS registry in the form of a digital newsletter.